The long-term effects of empagliflozin (Jardiance) in patients with chronic kidney disease were published on 2025-01-01. This publication details findings from the EMPA-KIDNEY study, which investigated heart and kidney protection with the drug.
Background
Empagliflozin is a medication studied for its potential benefits in patients with chronic kidney disease. The EMPA-KIDNEY study, formally known as "The Study of Heart and Kidney Protection With Empagliflozin," was designed to evaluate these protective effects.
Trial design
The EMPA-KIDNEY study focused on assessing the long-term effects of empagliflozin in individuals diagnosed with chronic kidney disease. The primary objective of the study was to investigate the drug's role in providing heart and kidney protection.
What this means
The publication of the EMPA-KIDNEY study results provides clinicians and researchers with comprehensive data on the long-term effects of empagliflozin in patients with chronic kidney disease. These findings are now available for review, contributing to the understanding of the drug's profile in managing heart and kidney health in this patient population.
Source
The information regarding the long-term effects of empagliflozin was published on 2025-01-01 in an article indexed by PubMed. The source document can be accessed via pubmed.ncbi.nlm.nih.gov.